CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...